Preliminary Results Announcement 2011/12



The Business of Science®



Jonathan Flint
Chief Executive

Kevin BoydGroup Finance Director

12 June 2012

Agenda



- Highlights
- Financial Summary
- Operational Review
- Summary and Outlook

Highlights



The Business of Science®

- Strong performance across all markets and territories
- Organic and Acquisitive growth
- Product and Process innovation
- Leveraging the OI Brand
- Increased final dividend

An excellent first year of the 14 Cubed plan



Three Elements of the 14 Cubed Plan



The Business of Science®

Organic Growth

- Structural growth in Nanotechnology
- Research and Industrial Markets remain robust
- Strong new product pipeline
- Efficiency
 - Productivity and margin improvements
- Targeted Acquisitions
 - Omicron Nanotechnology
 - Omniprobe
 - Platinum Medical Imaging

Global Diversity



- Europe
- North America
 - Asia
- Opportunities in BRIC and other emerging markets





The Business of Science®

Financial Review Kevin Boyd

Highlights



	2011/12	2010/11	Change
Orders (£m)	337.8	273.5	23.5%
Revenues (£m)	337.3	262.3	28.6%
Adjusted operating profit (£m)	42.1	28.1	49.8%
Return On Sales (%)	12.5%	10.7%	+1.8pp
Adjusted profit before tax (£m)*	42.0	26.2	60.3%
Adjusted EPS (pence)*	61.6	41.5	48.4%
Dividend (pence)	10.0	9.0	11.1%
Net Cash (£m)	35.1	13.1	22.0

^{*}Adjusted numbers are stated to give a better understanding of the underlying business. Details of adjusting items can be found in Note 2 of the Preliminary Statement


Segments



	Nanotechnology		Industrial						
	Tools		Products			Service		Total	
	2011/12	2010/11	2011/12	2010/11	4	2011/12	2010/11	2011/12	2010/11
	£m	£m	£m	£m		£m	£m	£m	£m
External revenue	153.3	121.4	128.0	98.5		56.0	42.4	337.3	262.3
Inter-segment revenue	0.6	0.4	1.1	2.0		0.3	0.1		
Sector revenue	153.9	121.8	129.1	100.5		56.3	42.5		
Adjusted operating profit	17.3	14.6	13.8	6.1		11.0	7.4	42.1	28.1
•									
Return on sales	11.2%	12.0%	10.7%	6.1%		19.5%	17.4%	12.5%	10.7%
	111270	12.070	1011 70	0.170		7010 70	171170	1210 /0	1011 /0


Sales Bridge






Sales by Geography






Sales by Market Segment





Profit Bridge






Efficiencies



The Business of Science®




—Sales/employee

-Value Add Index




Cash






Pensions






Orders






Sales Progress





Profit and Margin Progress







The Business of Science®

Operational Review Jonathan Flint

Three Business Sectors



The Business of Science®

Nanotechnology Tools



Nanoanalysis



NanoScience



Plasma Technology



Omicron NanoTechnology

Industrial Products



Industrial Analysis



Superconducting Wire



Austin



Magnetic Resonance

Service



OI Service




Service elements of other two sectors

NanoTechnology Tools


High-performance technology products for research and industry



- New product introductions driving organic growth
- Benefiting from increased investment in nanotechnology
- Leveraging added value from combined sector offering











Industrial Products

Analytical systems for Quality Control, Environmental and Compliance Testing for industry and research



- Diverse range of global markets and applications
- Process improvements driving productivity
- Launch of X-MET7500 exceeded expectations
- Opportunities in the steel and metals market





Service

OXFORD

Service, support, training, refurb, consumables, accessories

- Increased installed base
- Adoption of service contract model in Asia
- CT/MRI Service business establishing strong market presence in North America



Summary and Outlook





- Strong growth and record profitability
- Increased investment in people and product development
- Acquisition programme on track
- Markets remain strong despite macro-economic uncertainty
- Well positioned for further growth

Disclaimer



The Business of Science®

This presentation is prepared for and addressed to authorised persons within the meaning of the Financial Services and Markets Act 2000 (FSMA). The information contained in this presentation is not for publication, distribution or reproduction, in whole or in part, to any persons outside the jurisdiction of this Act. The Company, its Directors, employees, agents or advisers do not accept or assume responsibility to any other person to whom this presentation is shown or into whose hands it may come and any such responsibility or liability is expressly disclaimed.

Statements contained in this presentation are based on the knowledge and information available to the Company's Directors at the date it was prepared and therefore the facts stated and views expressed may change after that date. By their nature, any statements concerning the risks and uncertainties facing the Company in this presentation involve uncertainty since future events and circumstances can cause results and developments to differ materially from those anticipated. To the extent that this presentation contains any statement dealing with any time after the date of its preparation such statement is merely predictive and speculative as it relates to events and circumstances which are yet to occur. The Company undertakes no obligation to update these forward-looking statements.

The information in this presentation shall not constitute or be deemed to constitute any offer or invitation to invest in or otherwise deal in shares or other securities of Oxford Instruments plc.

All information in the presentation is the property of Oxford Instruments plc.